CC
AGIO icon

Callan Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Callan Capital’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-10,000
Closed -$419K – 45
2016
Q2 		$419K Buy
10,000
+3,000
+43% +$148K 0.17% 44
2016
Q1 		$284K Buy
+7,000
New +$299K 0.12% 48

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Callan Capital's AGIO Position: Q3 2016 in Review

Callan Capital sold out of Agios Pharmaceuticals (AGIO) in Q3 2016, closing a stake of 10,000 shares — an estimated $419K sold.

Callan Capital first reported a position in AGIO in Q1 2016 and held it in 2 quarters. The position peaked at $419K in Q2 2016. 163 funds tracked by Wall St. Rank hold AGIO as of Q3 2016.

  • Callan Capital reported no remaining Agios Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Callan Capital sold 10,000 Agios Pharmaceuticals shares in Q3 2016, an estimated $419K.
  • Callan Capital first reported a position in Agios Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • Callan Capital's Agios Pharmaceuticals position peaked at $419K in Q2 2016.
  • 163 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2016.

Based on Callan Capital's 13F filing for Q3 2016, filed 15 Nov 2016.